Cephalon Receives Approvable Letter for Sparlon for the Treatment of ADHD in Children and Adolescents
Sparlon is a new formulation and proprietary dosage strength of modafinil, the active ingredient in Provigil (modafinil) Tablets [C-IV], which is approved for the treatment of adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder. Provigil is not approved to treat ADHD and is available only in 100 mg and 200 mg strengths. If approved, Sparlon is expected to be available in early 2006.
Posted: October 2005
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of drugclasses.com in your inbox.